**Supplementary Table 2. Associations of PD-L1 expression and genomic mutations with survival outcome in mRCC patients with ICI plus TKI treatment (n = 52)**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **PFS2** | | **OS** | |
|  | **HR(95%CI)** | **P value** | **HR(95%CI)** | **P value** |
| **PD-L1 expression** |  |  |  |  |
| Positive vs Negative | 0.573(0.103-3.193) | 0.527 | 0.667(0.068-6.500) | 0.727 |
| **Genomic mutations (Yes vs No)** |  |  |  |  |
| PBRM1 | 0.606(0.081-4.546) | 0.626 | 0.656(0.086-5.019) | 0.685 |
| VHL | 1.734(0.573-5.244) | 0.330 | 1.538(0.426-5.553) | 0.511 |
| SETD2 | 2.141(0.752-6.092) | 0.154 | 1.748(0.543-5.626) | 0.349 |
| ARID1A | 0.041(0.020-10.672) | 0.306 | 0.041(0.031-17.402) | 0.402 |
| BAP1 | 0.551(0.073-4.143) | 0.563 | 0.716(0.093-5.507) | 0.748 |
| PTEN | 0.046(0-168.022) | 0.566 | 0.046(0-971.832) | 0.622 |